Our laboratory is devoted to investigating the pathogenesis and immune response to mycobacterial species, especially M. tuberculosis, with the main interest in the immune responses induced by vaccines. More recently, our knowledge and expertise evaluating the cellular and molecular immune responses to Bacille Calmette-Guerin (BCG) and additional anti-TB vaccine candidates, is being applied to evaluate novel vaccine candidates and therapeutics against SARS-CoV-2 (causative agent of COVID-19).
In our laboratory, we have the ability to test how effective the immune response is against different clinical strains of bacterial and viral infections. Our goal is to better understand the immune response to different vaccine candidates using multiparametric and transcriptional unbiased analysis of the cells induced after vaccination. We also utilize metabolic profiles, high throughput and histologic methods, and computational tools to evaluate immune responses.
Furthermore, as the director of the CSU Flow Cytometry and Cell Sorting facility and due to our lab experience using flow cytometry as an analytical tool, our laboratory has been implementing and developing new tools for multicolor flow cytometry analysis. We are currently using algorithms that automatically identify cell populations according to their marker expression profiles. These computational methods not only can identify rare populations, but also to match cell populations across samples, and statistically compare features between different populations. The algorithms we recently published in Scientific Reports (Cyto-Feature Engineering: A Pipeline for Flow Cytometry Analysis to Uncover Immune Populations and Associations with Disease) provides an unsupervised analysis, allowing an unbiased investigation of cytometry data.
Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAC-TB)
The Henao Tamayo and Podell labs are leading a CSU team on a $1.2 million subcontract to accelerate research progress in tuberculosis vaccines. Objectives are to understand the immune responses that prevents initial infection, the establishment of latent infection, and the transition to active TB disease. There is currently only one vaccine for TB and it only reliably works on children.
Vaccine induced memory immunity in tuberculosis
There are several vaccine candidates that give protection against the laboratory strains H37Rv and Erdman at a level comparable to the BCG vaccine. However, whether different vaccine types give equivalent or different levels of memory T cell subsets is unknown, and whether these vaccines will be equally protective against newly emerging highly virulent clinical strains is equally unaddressed.view project
A whole virion vaccine for COVID-19 produced via a novel inactivation method: results from animal challenge model studies
Izabela K Ragan, Lindsay M Hartson, Taru S Dutt, Andres Obregon-Henao, Rachel M Maison, Paul Gordy, Amy Fox, Burton R Karger, Shaun T Cross, Marylee L Kapuscinski, Sarah K Cooper, Brendan K Podell, Mark D Stenglein, Richard A Bowen, Marcela Henao-Tamayo, Raymond P Goodrich
bioRxiv 2020.11.13.381335; doi: https://doi.org/10.1101/2020.11.13.381335
BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis.
Tiwari S, Dutt TS, Chen B, Chen M, Kim J, Dai AZ, Lukose R, Shanley C, Fox A, Karger BR, Porcelli SA, Chan J, Podell BK, Obregon-Henao A, Orme IM, Jacobs WR Jr, Henao-Tamayo M.
Vaccine. 2020 Oct 21;38(45):7156-7165. doi: 10.1016/j.vaccine.2020.08.004. Epub 2020 Sep 23.
Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research.
Rampacci E, Stefanetti V, Passamonti F, Henao-Tamayo M.
Pathogens. 2020 Aug 6;9(8):641. doi: 10.3390/pathogens9080641.
Fox A, Dutt TS, Karger B, Obregón-Henao A, Anderson GB, Henao-Tamayo M.
Curr Protoc Cytom. 2020 Jun;93(1):e74. doi: 10.1002/cpcy.74.
Cyto-Feature Engineering: A Pipeline for Flow Cytometry Analysis to Uncover Immune Populations and Associations with Disease
Amy Fox, Taru S. Dutt, Burton Karger, Mauricio Rojas, Andrés Obregón-Henao, G. Brooke Anderson, Marcela Henao-Tamayo
Scientific Reports volume 10, Article number: 7651 (2020)
Lab Principal Investigator (PI)
Director, CSU Flow Cytometry Facility
Research Scientist III
Research Associate II
CSU Flow Cytometry Core Manager
Research Associate II, Lab Manager
news and updates
Marcela Henao-Tamayo discusses her tuberculosis research, COVID-19 vaccine projects and Women’s History Month with Colorado State University.
While Marcela Henao Tamayo’s ongoing primary research focus is on tuberculosis, she is currently working with colleagues on developing a COVID-19 vaccine. Her conversation with CSU President Joyce McConnell highlights the scope, caliber and impact of CSU research.
An interdisciplinary CSU team is advancing a COVID-19 vaccine candidate with additional NIH support, that relies on riboflavin and UV light technology to create inactivated virus.
Lab: Microbiology room C210
Office: Microbiology room B104